Telatinib Shows Promise in Treating Advanced Solid Tumors

Strategic Insights -

Researchers in the Netherlands conducted a phase I dose escalation study to evaluate the safety and tolerability of telatinib, a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit. The study involved 53 patients with solid tumors who were refractory to standard therapies or had no standard therapy available. The results showed that telatinib was rapidly absorbed and well-tolerated, with a maximum tolerated dose not reached. The study also demonstrated a dose-dependent increase in VEGF levels and a decrease in plasma soluble VEGFR-2 levels, indicating potential anti-angiogenic activity.

Key Takeaways:

  • Telatinib is an orally available tyrosine kinase inhibitor that targets multiple pathways involved in angiogenesis, including VEGFR-2, VEGFR-3, PDGFR-beta, and c-Kit.
  • The phase I dose escalation study enrolled 53 patients with solid tumors refractory to standard therapies or with no standard therapy available.
  • Doses of continuously administered telatinib were escalated from 20 mg once daily to 1,500 mg twice daily, with most frequently observed drug-related adverse events being nausea (26.4%) and hypertension (20.8%).
  • Telatinib was rapidly absorbed, with a median time to peak concentration (t(max)) lower than 3 hours after dose, and a nearly dose-proportional increase in exposure was observed with substantial variability.
  • Biomarker analyses showed a dose-dependent increase in VEGF levels and a decrease in plasma soluble VEGFR-2 levels, with a plateau at 900 mg twice daily.
  • A decrease in tumor blood flow (K-trans and IAUC(60)) was observed with dynamic contrast-enhanced magnetic resonance imaging, indicating potential anti-angiogenic activity.
  • The best tumor response was stable disease, observed in 50.9% of patients.
  • Telatinib was safe and well-tolerated up to 1,500 mg twice daily, and the researchers recommended 900 mg twice daily as the optimal dose for subsequent phase II studies.

Statistics:

  • 53 patients were enrolled in the study.
  • 26.4% of patients experienced nausea.
  • 20.8% of patients experienced hypertension.
  • 50.9% of patients achieved stable disease as the best tumor response.
  • Telatinib was rapidly absorbed, with a median time to peak concentration (t(max)) lower than 3 hours after dose.

Sources:

  • Eskens, F.A.L.M., et al. (2009). Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor beta, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 27(25), 4169-4176.
  • Angiogenesis Weekly editors (2009). Telatinib Shows Promise in Treating Advanced Solid Tumors. Angiogenesis Weekly, Copyright 2009, NewsRx.com.